Engineering drugs instead of discovering them.

We are building a synthetic biology platform to develop a new type of drug called synthetic live biotherapeutics. We engineer probiotics with modules offering unprecedented therapeutic activities to tackle diseases for which conventional drugs have reached their limits.

 

Synthetic live biotherapeutics
the next
generation drug.

 

TATUM's team

JF.jpg

For this seeker of disruptive technologies, passionate about biotechnology and entrepreneurship, we are at the dawn of a synthetic live biotherapeutic revolution where TATUM will play a key role.

Kevin.jpg

Kevin Neil, MSc
Co-Founder & CTO

Kevin, an exceptional synthetic biologist, turned the radically new technological approach developed by TATUM bioscience into a reality. He is convinced that applying synthetic biology principles to the engineering of drugs holds great promise.

Seb.jpg

Sébastien Rodrigue, PhD
Co-Founder & CSO

Professor at the Université de Sherbrooke, Sébastien has positioned his laboratory at the forefront of Canadian synthetic biology. His profound desire to have a positive impact on the world led him to imagine the breakthrough technology at the heart of TATUM bioscience.

The advisers

Louise Proulx.jpg

With 30 years of R&D management in the pharma industry, Louise has held VP positions in successful companies: BioChem Pharma, ViroChem Pharma, and Vertex Canada. She also worked in the VC sector as Development Officer at Therillia and Venture Partner at Sanderling.

Le_Mai_Tu_recadrée.jpg

Urologist and full Professor at the Université de Sherbrooke, Dr. Tu’s drive is entirely dedicated to her patients. Over the course of her career, she has been pivotal in the adoption of innovative treatment protocols. As a principal investigator, she has led numerous clinical research projects and authored over 50 peer-reviewed articles.

PC.jpg

Equity research analyst specialized in the biotech and pharma sectors, Pierre has worked for several financial institutions and investment banks (BGC Partners, Bryan, Garnier & Co, ODDO BHF). Recently, he was involved in the IPO of Moderna Therapeutics. He is now Director Equity Analyst Healthcare at UBP Geneva, Switzerland.

Vincent B.jpg

Professor at the Université de Sherbrooke, Vincent is a world-renowned expert in bacterial conjugation. He has authored more than 50 peer-reviewed articles and has been an invited speaker at many symposiums around the world.

 

Let's get in touch.

Are you interested in collaborating with us? Do you want to join the synthetic live biotherapeutic revolution? 

Feel free to contact us! We are looking forward to hearing from you!

TATUM bioscience is supported by:

©2020 TATUM Bioscience Inc. Background image by Qimono.